Industry Overview

Glaucoma treatment market was valued at $6.7 billion in 2025 and is projected to reach $10.4 billion by 2035, growing at a CAGR of 4.7% during the forecast Period (2026-2035). The market is experiencing significant growth, driven by an aging population, rising prevalence of associated conditions (diabetes, hypertension), increased awareness, and technological advancements like MIGS and AI diagnostics, all boosting demand for drugs, surgeries, and devices. Key factors include technological innovation, shifting work models, increasing screen time, and efforts in early diagnosis, while challenges involve generics and post-pandemic healthcare recovery.

Market Dynamics 

Aging Population and Increasing Glaucoma Prevalence

The global glaucoma treatment market is primarily driven by the steady rise in the aging population, as the risk of glaucoma increases significantly with age. Longer life expectancy across developed and emerging economies has resulted in a growing pool of patients requiring long-term disease management. In addition, improved screening programs and greater awareness among both patients and clinicians are leading to earlier diagnosis and higher treatment initiation rates. Since glaucoma is a chronic and progressive condition, diagnosed patients typically require lifelong therapy, supporting sustained demand for medications, laser treatments, and surgical interventions.

Advancements in Treatment Options and Delivery Technologies

Continuous innovation in glaucoma therapeutics and devices is another key market driver. Pharmaceutical advancements, including novel drug classes, fixed-dose combinations, and sustained-release formulations, aim to improve intraocular pressure control and address poor patient adherence associated with daily eye drops. At the same time, technological progress in surgical and laser-based treatments, particularly minimally invasive glaucoma surgery (MIGS), is expanding treatment options beyond conventional procedures. These innovations enhance clinical outcomes, reduce complication risks, and increase physician and patient acceptance, thereby supporting market growth.

Expanding Healthcare Access and Investment in Ophthalmic Care

Rising healthcare expenditure and improving access to ophthalmic services, particularly in emerging markets, are contributing to the expansion of the glaucoma treatment market. Governments and private healthcare providers are investing in eye care infrastructure, specialist training, and diagnostic capabilities, leading to higher detection and treatment rates. In parallel, broader insurance coverage and reimbursement support for glaucoma therapies and procedures are improving affordability and uptake. This expansion of treated patient populations, especially in Asia-Pacific and other developing regions, is strengthening global demand across both drug-based and procedural treatment segments.

Market Segmentation

• Based on the disease indication, the market is segmented into closed-angle glaucoma (CAG), open-angle glaucoma (OAG), secondary glaucoma, and congenital glaucoma.
• Based on the distribution channel, the market is segmented into hospitals pharmacy, retail pharmacy, and online pharmacy.
• Based on the drug class, the market is segmented into prostaglandin analogues, alpha agonist, cholinergic, beta blockers, and carbonic anhydrase inhibitors.

Prostaglandin Analogues Segment to Grow at a Considerable Market Share

Among all the segments, prostaglandin analogues under the drug class category emerge as the largest and most dominant segment, leading the global glaucoma treatment market. This dominance is primarily attributed to their strong clinical efficacy in reducing intraocular pressure, favorable once-daily dosing regimen, and a well-established safety profile compared with other drug classes such as beta-blockers or cholinergic agents. Prostaglandin analogues are widely recommended as first-line therapy for open-angle glaucoma (OAG), which itself represents the most prevalent disease indication globally, further reinforcing their volume leadership. High prescription rates across hospitals and retail pharmacies, strong physician familiarity, and the availability of both branded and generic formulations support broad patient adoption across developed and emerging markets. As a result, prostaglandin analogues consistently account for the largest revenue share and are expected to continue leading the global glaucoma treatment market throughout the forecast period.

Open Angle Glaucoma (OAG): A Key Segment in Market Growth

Open angle glaucoma (OAG) represents the single most influential segment in the global glaucoma treatment market and is the primary contributor to overall market growth. OAG accounts for the majority of diagnosed glaucoma cases worldwide due to its high prevalence and typically asymptomatic early-stage progression, which necessitates long-term disease management once detected. Patients with OAG often require lifelong pharmacological therapy, frequently starting with prostaglandin analogues and progressing to combination drug regimens, laser procedures, or minimally invasive glaucoma surgeries as the disease advances.

This extended treatment duration significantly increases cumulative spending per patient compared with other glaucoma types. In addition, growing awareness campaigns and routine eye examinations are improving early detection rates of OAG, particularly in aging populations across North America, Europe, and the Asia-Pacific. From a commercial perspective, OAG benefits most from therapeutic innovation, including sustained-release drug delivery systems, novel drug classes, and the rapid adoption of minimally invasive glaucoma surgery devices, all of which are primarily indicated for OAG patients. These factors collectively position Open Angle Glaucoma as the dominant and fastest-expanding disease indication, making it the key segment driving long-term revenue growth in the global glaucoma treatment market.

Regional Outlook

the global glaucoma treatment market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global glaucoma treatment market and accounts for the largest country-level share of total revenue. This leadership is driven by a high prevalence of diagnosed glaucoma, strong awareness and screening practices, and early adoption of advanced treatment modalities. The US has a large aging population, which significantly increases the at-risk patient pool, and routine eye examinations enable earlier diagnosis compared with many other countries. From a treatment standpoint, the country shows high utilization of premium-priced pharmacological therapies, including branded prostaglandin analogues, fixed-dose combinations, and newer drug classes, alongside rapid uptake of minimally invasive glaucoma surgery (MIGS) and advanced laser systems.

Favorable reimbursement frameworks through public and private insurers further support access to both drug-based and procedural treatments, increasing per-patient spending levels. In addition, the presence of leading pharmaceutical and medical device companies, a strong clinical trial ecosystem, and continuous product approvals contribute to market expansion and innovation leadership. High healthcare expenditure, well-established ophthalmology infrastructure, and patient willingness to adopt advanced therapies collectively position the United States as the dominant country in the global glaucoma treatment market, holding a major share and setting clinical and commercial benchmarks for other regions.

Market Players Outlook

The major companies operating in the global glaucoma treatment market include AbbVie (Allergan), Novartis AG, Merck & Co., Inc., Pfizer Inc., Santen Pharmaceutical Co., Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In June 2025, Perfuse Therapeutics announced positive results from Phase 2 clinical trials of PER-001, an intravitreal implant aimed at treating glaucoma and diabetic retinopathy, potentially becoming the first disease-modifying treatment for these conditions. The trials showed significant improvements in vision, retinal ischemia, and optic nerve structure for patients, with favorable safety profiles. In the glaucoma trial, 22.2% of low-dose and 37.5% of high-dose patients experienced marked vision improvement, compared to 0% in the control group, while no treated patients suffered significant vision loss. These results, which outperformed natural disease history, signal promise for effective interventions against global blindness. Ph2b/3 trials are slated to begin in late 2025.
• In July 2025, New Eyetronic therapy was introduced as the first non-invasive glaucoma treatment in the US. This therapy provides external neural stimulation to the optic nerve, aiming to halt or reverse vision loss caused by glaucoma, a leading cause of irreversible blindness. Traditional treatments focus primarily on lowering intraocular pressure (IOP), which is not always sufficient. The therapy is part of a clinical trial led by Dr. Sunita Radhakrishnan, who emphasizes its potential to improve visual function in patients with progressive glaucoma despite adequate IOP control. Preliminary results from the study are expected in early 2026.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global glaucoma treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.